Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α–kinoid†

These results show that IFN-K is well tolerated, immunogenic, and significantly improves disease biomarkers in SLE patients, indicating that further studies of its clinical efficacy are warranted.